NIH-CAP 2006-07 Participating Companies - 11/2007



NIH-CAP 2006-07 Participating Companies

|AbleLink Technologies, Inc. |

|Colorado Springs, CO |

|Daniel Davies |

|Tel: 719-592-0347 |

|Email: dan@ |

| |

|AbleLink Technologies™ has pioneered technologies which maximize independence and reduce costs for |

|individuals needing specialized supports to live independently. The HomeLife Technology Suite TM |

|delivers easy to use health care instructions using text, video and audio; provides automated |

|reminders to take medications or perform exercises; tracks activity; and remotely communicates health |

|information. This system enables seniors, their family members or home health care providers to |

|perform health care tasks more accurately, using a unique person-centered approach which does not yet |

|exist in the industry. AbleLink is seeking expansion funding, strategic partners and home health care |

|organizations interested in cost-effective strategies for serving the expanding senior population. |

| |

|Advanced Liquid Crystal Tech, Inc. |

|Summit, NJ |

|Patricia Cladis |

|Tel: 908-273-0187 |

|Email: @ |

| |

|A collaboration of physicists and engineers using state-of-the-art techniques and knowledge to turn |

|theory into practice Our products: 1. Hyperpolarimeter - A tool for measuring the magnetization of |

|gases enabling Magnetic Resonance Imaging (MRI) of empty spaces – (lungs, heart, sinuses etc) and |

|tracking of the uptake of oxygen in the brain and other soft tissues in the body. 2. Hyperpolarizer - |

|A portable, fully automated device for polarizing He3, thus enabling MRI of soft tissues and empty |

|spaces, e.g. lungs, sinuses, etc. Our goal is to partner with an existing manufacturer of MRIs and MRI|

|related products to dominate the Hyperpolarized gas market as it develops. |

| |

|Advanced Liquid Logic |

|Research Triangle Pk, NC |

|Richard West |

|Tel: 919-287-9010 |

|Email: rwest@liquid- |

| |

|Advanced Liquid Logic’s digital microfluidics is a lab-on-a-chip technology based on direct, |

|programmable manipulation of discrete droplets using electrical fields. It enables complex liquid |

|handling to be implemented in software with no pumps, valves, or pipes. The Company has implemented |

|rapid and sensitive clinical chemistry and immunoassays on chip and has demonstrated the feasibility |

|of PCR and DNA sequencing. Ultimately complex test panels will be performed on low-volume samples with|

|a PDA-like instrument. The Company has the team (10 PhD’s) and the patent position (30 patents issued |

|or pending) to succeed and seeks partners to take products to market. |

| |

|Advantagene |

|Waban, MA |

|Estuardo Aguilar-Cordova |

|Tel: 617-916-5445 |

|Email: eaguilar@ |

| |

|Progression and recurrence after initial cancer therapy is a key underserved and unmet medical need. |

|Advantagene is focused on addressing this need through simple products that improve the outcome of |

|standard radiation, surgery or chemotherapy. Advantagene’s lead technology, Gene Mediated Cytotoxic |

|Immunotherapy (GMCI™), generates a patient-specific response from a non-patient-specific product. It |

|generates an in-situ tumor-specific vaccine for a targeted, systemic response against residual tumor |

|cells or occult micrometastases. GMCI™ can be applied to a variety of tumor types. Advantagene has |

|positive results from a completed Phase 2 and multiple Phase 1 human clinical trials. |

| |

|AdviTech, Inc. |

|San Antonio, TX |

|Wesley Krueger |

|Tel: 210-697-0880 |

|Email: wkruegermd@ |

| |

|Advitech, Inc. is a company created to develop technology to prevent spatial disorientation and motion|

|sickness. The company has a product specifically for the aviation industry (i.e. the Avionix device), |

|and a product for other applications where individuals have hypersensitivity to motion sickness (i.e. |

|the X-Motion device). The target market is aviation, with the intent to improve safety and prevent the|

|mishaps secondary to some of the illusions causing spatial disorientation. Hardware and software |

|technology have been developed which provides the pilot with more visual information about his head |

|and body position in space. The hardware is comprised of a heads up display system and the software |

|utilizes an artificial horizon and other lines or symbology to display movement and spatial |

|orientation. For military application, the software technology can be displayed in the standard HUD |

|device to provide synergistic information about his or her orientation in space. Other flight |

|personnel can benefit, because they frequently lack visual reference, as the device can assist them |

|with orientation and prevent the ill effects of motion sickness. |

| |

|America Living Well |

|Princeton, NJ |

|Rick Weiss |

|Tel: 609-497-4600 |

|Email: weiss@ |

| |

|America Living Well will become the leader in community-centric obesity initiatives improving the |

|health of children and adults. ALW is a community health web portal, leveraging: • proprietary and |

|proven web-based health, nutritional and behavioral modification technology; • a robust, scaleable, |

|customizable online platform with social networking and local content; • a rewards system fostering |

|multi-channel revenue streams; • the power of community (business and health system partnerships) |

|achieving sustainable impact. A $500K NIH SBIR grant funded a prototype, Princeton Living Well. The |

|company seeks funding for expansion. Five year goal – over 1000 communities generating significant |

|revenue in multi-billion market. |

| |

|Aphios Corporation |

|Woburn, MA |

|Trevor Castor |

|Tel: 781-932-6933 |

|Email: tcastor@ |

| |

|Aphios Corporation () is developing enabling SuperFluids? technology platforms to |

|improve the discovery of natural therapeutics and manufacturing of rare and complex bioactive |

|molecules, the nanodelivery of small molecules and therapeutic proteins, and the inactivation of |

|viruses in natural and recombinant biologics. SuperFluids? are gases such as carbon dioxide and |

|alcohols like ethanol which, when compressed, exhibit enhanced thermodynamic properties of |

|penetration, selection, solvation and expansion. Utilizing these enabling technology platforms, Aphios|

|is also developing enhanced therapeutics for the prevention and treatment of certain infectious |

|diseases, cancers and CNS disorders from a unique library of marine microorganisms and medicinal |

|plants. |

| |

|Artann Laboratories, Inc |

|Trenton, NJ |

|Noune Sarvazyan |

|Tel: 512-996-8565 |

|Email: nsarvaz@ |

| |

|Artann Laboratories (Artann) is a research and development company with mission to develop and |

|commercialize novel high-tech products and technologies. Patented inventions of Artann include a |

|variety of novel medical imaging modalities: mechanical imaging, new approaches to ultrasonic and |

|magnetic resonance elasticity imaging and shear wave elasticity imaging. Artann has also developed and|

|patented several medical diagnostic devices, including skin elasticity analyzer; muscle water content |

|tester, colonoscopy force monitor, portfolio of scanning bone ltrasonometers, and several applications|

|of the time reversal acoustics. The main focus of company NIH CAP activity is development of FDA |

|application for prostate cancer detection technology. |

| |

|Assenti |

|Louisville, KY |

|John Naber |

|Tel: 502-852-7910 |

|Email: john.naber@louisville.edu |

| |

|Assenti creates new therapeutic management techniques enabled by biosensors. Assenti is currently |

|developing an intraocular pressure (IOP) monitoring system, small enough to be implanted into the eye.|

|The information provided by this system improves glaucoma therapy and prevents blindness. Glaucoma is |

|the second leading cause of blindness in the USA and causes $3 billion is excess costs for Medicare |

|insurance. Assenti is in preclinical trials and seeks to raise $10 million in private equity |

|investments for further system development, clinical trials, and market launch. |

| |

|Barron Associates, Inc. |

|Charlottesville, VA |

|B. Eugene Parker, Jr. |

|Tel: 434-973-1215 |

|Email: parker@ |

| |

|Barron Associates, Inc. is an engineering/scientific R&D and professional technical services company. |

|Since its inception in 1983, Barron Associates has developed applications for commercial and |

|government clients in diverse areas ranging from flight vehicle guidance and control systems to |

|medical devices. Our approach to commercialization of technology is to form joint ventures based, in |

|part, on Barron Associates' SBIR technologies. One technology that the company is presently looking to|

|commercialize is a wireless biosignal monitoring system that can be used, for example, to implement a |

|fully untethered, high-performance (e.g., 16 channels, 2,000 16-bit samples per channel) digital |

|electromyography (EMG) system. |

| |

|Behavioral Research, Inc |

|ALBUQUERQUE, NM |

|Robin Inlander |

|Tel: 505-265-4826 |

|Email: robin@ |

| |

|Behavioral Research, Incorporated (BRI) is a small, for-profit, woman-owned company founded by a M.D.,|

|MPH. BRI's mission is to enhance the well-being of individuals, families and communities through the |

|development and distribution of innovative, customer-driven, research-based interventions in |

|behavioral health. BRI’s interactive, computer-based, Pregnancy Information Program (PIP), funded by |

|NIH/NIDA, is directed at the needs of pregnant woman and their providers. The PIP has been shown to |

|accurately identify behaviors that may adversely affect birth outcomes, engage respondents in making |

|positive changes, provide a powerful timesaving tool for busy clinicians and ultimately save money. |

|BRI seeks strategic partners and customers. |

| |

|BIOMEC Inc. |

|Cleveland, OH |

|Robert Purcell |

|Tel: 216-937-2800 |

|Email: bpurcell@ |

| |

|BIOMEC INC, which began operations in 1998, is focused on the development and commercialization of |

|innovative medical devices. One promising device that is being developed and is nearing |

|commercialization is a low-power, lightweight, portable and non-invasive pneumothorax (collapsed lung)|

|detector. This device fulfills a strong unmet need in the first responder markets, including EMTs, |

|Emergency Physicians, as well as a large Military market. BIOMEC has built multiple prototypes and |

|completed successful clinical testing on the device. BIOMEC is currently finalizing product |

|development and preparing the regulatory trials. BIOMEC is currently seeking additional capital to |

|complete clinical trials, obtain FDA approval and launch the commercial device. |

| |

|BioMed Software Inc. |

|Newton, MA |

|John McCall |

|Tel: 617-694-4460 |

|Email: jmccall@ |

| |

|BioMed Software Inc. is the developer of ManRay - Effective Dose Software. No methodology currently |

|exists for rapid and customizable dose determination for radiographic procedures. We deliver |

|user-friendly software for the calculation of effective patient dose from all diagnostic x-ray |

|procedures. User input, requiring only a few seconds, specifies all characteristics of the photon |

|beam, type of examination, phantom gender and size. Full capability of simulating planar radiography, |

|CT (including non-contiguous slices and gantry tilt) and fluoroscopy (including C-arm and table |

|arrangements) is included. Calculations are performed via Monte Carlo simulation using a |

|state-of-the-art transport code available in the public domain. Simulation times of only a few minutes|

|lead to statistical accuracies of 20,000 extracts, 100,000 purified and semipurified compounds |

|from over 30,000 field collected basidiomycetes and ascomycetes (mushrooms). Most of our collection is|

|from unculturable species. Our compound libraries area rich source of novel compounds, many of then |

|synthesized under conditions of environmental stress. LifePharms is presently screening this natural |

|product library for novel anticancer and antiviral compounds. We are seeking strategic partners to |

|discover lead compounds in additional therapeutic areas including antibacterial, immune suppressants, |

|cholesterol lowering, etc. For more information see . |

| |

|LifeSensors Inc |

|Malvern, PA |

|Tauseef Butt |

|Tel: 610-644-8845 |

|Email: butt@ |

| |

|LifeSensors is a privately held biotechnology company located 35 miles west of Philadelphia. |

|LifeSensors SUMOpro® fusion technology enhances the expression and solubility of difficult to express |

|proteins in E. coli, yeast, insect, and mammalian cells. LifeSensors patented technology is used to |

|express and purify proteins for research, diagnostics and therapeutic use. LifeSensors performs |

|contract expression and purification services. LifeSensors is expressing important families of |

|proteins such as de-ubiquitinases, kinases and GPCRs to develop functional protein arrays for drug |

|discovery, diagnostics and toxicology studies. |

| |

|Lynntech, Inc. |

|College Station, TX |

|Scott McKenzie |

|Tel: 979-693-0017 |

|Email: scott.mckenzie@ |

| |

|Lynntech is a Texas-based technology and commercialization company with over 115 U.S. patents and |

|corresponding foreign filings in numerous areas of innovation. Our current offering focuses on a new |

|therapeutic drug and simple device to treat diverse dermal, ophthalmic, dental and burn wound |

|infections that are increasingly becoming resistant to conventional antibiotics. We have developed a |

|lead compound(s) that have shown specific antimicrobial activity against bacteria, fungi, yeast, and |

|mold without toxic impact on healthy mammalian tissue cells in vitro. This patent pending drug and |

|device utilize photodymanic therapy properties of chemically modified nanostructured fullerenes |

|(a.k.a. buckeyballs) which target pathogens throughout the infection and are activated to a biocidal |

|status locally by targeted ‘white light’. |

| |

|MandalMed, Inc. |

|SAN FRANCISCO, CA |

|Constance John |

|Tel: 415-495-5570 |

|Email: connie@ |

| |

|MandalMed is the first and only source of proprietary human Sertoli cells and is developing both |

|cellular therapy products and reproductive function toxicity assays for the diagnostic research |

|markets. A significant body of data shows that Sertoli cells reduce host rejection of allografted |

|cells during transplantation and increase the growth of certain cells such as neurons. Potentially, |

|these Sertoli cells have multiple treatment applications in important markets including Type 1 |

|diabetes, neurodegenerative diseases, and infertility due to deficiency or malfunctioning Sertolis. |

|MandalMed is seeking seed capital and to establish strategic alliances for development of cellular |

|therapeutics. |

| |

|MBF Bioscience (MicroBrightField, Inc.) |

|Williston, VT |

|Jeffrey Sprenger |

|Tel: 802-288-9290 |

|Email: jeff@ |

| |

|MBF Bioscience provides neuroscience researchers and cell biologists with microscopic image analysis |

|systems and solutions. Our products, Neurolucida® and Stereo Investigator® are used by over 1000 |

|research laboratories worldwide for neuron tracing, brain mapping, stereology and morphometric |

|analysis. AutoNeuron®, a new product developed under SBIR funding, automates the process of |

|reconstructing and analyzing neuron morphology from 3D images. MBF is a privately held, U.S. based, |

|company with offices in Europe and Japan and a dealer network covering East Asia, Australia and South |

|America. |

| |

|Mealtime Partners, Inc. |

|Azle, TX |

|Catherine Wyatt |

|Tel: 817-237-9991 |

|Email: catherine@ |

| |

|Mealtime Partners, Inc. is the developer and manufacturer of the Mealtime Partner Assistive Dining |

|Device. The Mealtime Partner is a new and innovative technology that permits individuals, who |

|otherwise cannot feed themselves, to eat without assistance after they are provided with food. It will|

|provide independence when eating for persons with impairments due to spinal cord injury, cerebral |

|palsy, multiple sclerosis, stroke, muscular dystrophy, birth defects, and old age. The Mealtime |

|Partner provides the foundation for a new industry serving the needs of the rapidly growing population|

|of elderly and disabled individuals who are unable to eat independently. |

| |

|Medical Decision Modeling Inc. |

|Indianapolis, IN |

|Harry J. Smolen |

|Tel: 317-704-3800 |

|Email: smolen@mdm- |

| |

|Medical Decision Modeling Inc.'s mission is to provide products and services that facilitate |

|cost-effective healthcare decisions. MDM's core competency lies in the development of interactive |

|software applications called medical decision models. These models clearly communicate the risks, |

|benefits, and costs of competing courses of care for medical conditions. MDM's target markets include |

|pharmaceutical companies, medical device manufacturers; and healthcare payers, providers, and |

|patients. MDM's corporate objective is to be the world leader in the development and dissemination of |

|medical decision models to payers (and those who market to them, e.g., pharmaceutical and device |

|companies), providers, and patients. |

| |

|Medical Directions, Inc |

|Tucson, AZ |

|John Harris Jr. |

|Tel: 520-722-1970 |

|Email: sharris@md- |

| |

|Medical Directions, Inc (MDI) is a privately-held small business specializing in online medical |

|education. MDI has developed an efficient, proprietary educational development and deployment software|

|platform. It has demonstrated in controlled studies that its educational programs are as effective as |

|live meetings by trained experts. MDI’s programs can be developed and deployed nationally and |

|internationally for a fraction of the cost of live meetings. MDI’s customers include thousands of |

|individual physicians, major academic medical centers, philanthropic organizations, health care |

|delivery systems, government agencies, and other entities seeking to provide effective medical |

|education at a lower cost. |

| |

|MediSpin Inc. |

|New York, NY |

|Brian Shanahan |

|Tel: 212-255-9948 |

|Email: bshanahan@ |

| |

|MediSpin, Inc. is an innovative medical communications company consisting of a team of knowledgeable, |

|experienced, creative professionals dedicated to meeting the educational, training, and marketing |

|needs of diverse healthcare, pharmaceutical, and academic specialists. Currently, MediSpin, working |

|with Duke University under NIMH Phase II grant funding, is developing an Internet-based software |

|prototype designed to assist physicians who treat ADHD children to implement evidence-based treatment |

|procedures. This product is designed to provide community physicians with tools that will allow them |

|to efficiently, effectively, and economically (both in time and cost) treat ADHD children. It will |

|also greatly enhance communication between the physician, parent and teacher. |

| |

|Mi-Co |

|Research Triangle Park, NC |

|Gregory Clary |

|Tel: 919-485-4819 |

|Email: gclary@mi- |

| |

|Mi-Co, the mobile data capture company, provides software to eliminate numerous pains of paper |

|forms-based business processes. Mi-Co’s enterprise Mi-Forms Software System provides flexible |

|electronic forms design for data capture using digital ink and has proven capabilities for handwriting|

|interpretation and verification, data validation and the communication of forms-based data. Mi-Forms |

|supports Tablet PCs, Digital Pens, Pocket PCs, signature capture devices and industry standard |

|software technologies. Mi-Co reaches historically paperwork intensive markets such as the healthcare |

|and government sectors through a growing network of over forty channel partners. |

|mi- |

| |

|MicroMRI Inc |

|Philadelphia, PA |

|Onne Ganel |

|Tel: 215-564-1002*15 |

|Email: oganel@ |

| |

|MicroMRI aims to provide imaging-based monitoring tools which are non-invasive, accurate, |

|readily-available and cost-effective. MicroMRI’s current products deliver microscopic-level images of |

|bone and cartilage architecture for arthritis and osteoporotic disease monitoring. The currently |

|available tools with adequate specificity are invasive: bone biopsies and arthroscopies. MicroMRI |

|delivers non-invasive methods to accurately evaluate these diseases. MicroMRI sells its systems for |

|research and is the world’s only company that provides research services for structural quantification|

|of bone changes during drug treatment in humans for pharmaceutical and academic research. MicroMRI |

|intends to obtain FDA clearance for its systems and market them in clinical markets. |

| |

|Micronics, Inc. |

|Redmond, WA |

|Karen Hedine |

|Tel: 425-895-9197 |

|Email: khedine@ |

| |

|Micronics has developed a unique, proprietary, rapid-test platform that produces sample-to-result |

|analyses in seconds to minutes. Tests are configured as miniaturized (credit card size) disposable |

|devices that can be used at point-of-care when highly sensitive and specific results are needed. |

|Products in development include molecular diagnostics for detection of sexually transmitted diseases, |

|enteric pathogens, fever-causing pathogens, and several rare cancers. An ABO/Rh typing test is also in|

|advanced development. The platform can be adapted to virtually any diagnostic assay where high quality|

|detection reagents exist. Micronics is focused on building strategic partnerships to market these |

|advanced products. |

| |

|MicroStrain Inc |

|Williston, VT |

|Mike Robinson |

|Tel: 802-862-6629 |

|Email: mirobinson@ |

| |

|MicroStrain is a privately held corporation based in Williston Vermont. We produce smart, wireless |

|sensors for strain, displacement & orientation monitoring. Our products are used in automotive, |

|aerospace, military, and medical applications for health monitoring of machines, structures, and |

|devices. Inertia-Link™, is MicroStrain’s latest wireless inertial measurement device. It uses |

|miniature gyroscopes and accelerometers for wearable motion analyses, eliminating the cables |

|associated with traditional motion trackers. On board intelligent processing combined with mobile |

|phone connectivity enable the patient’s biomechanical status to be tracked remotely. MicroStrain is |

|currently seeking partners to transition this technology into key medical monitoring applications. |

| |

|MIDI, Inc. |

|Newark, DE |

|Myron Sasser |

|Tel: 302-737-4297 |

|Email: myron@midi- |

| |

|MIDI Inc., for 18 years, has created and sold a gas chromatography- based system using fatty acid |

|composition for identification of bacteria. The current add-on product is a technique for rapid |

|identification of bacteria direct from blood culture bottles. This 30-minute procedure will be highly |

|competitive with current techniques that typically take one to three days. The savings in time result |

|in shorter hospital stay time for patients and greater precision in choice of antibiotic therapy. |

| |

|Mikro Systems, Inc. |

|Charlottesville, VA |

|Michael Appleby |

|Tel: 434-244-6480 |

|Email: appleby@ |

| |

|Mikro Systems, Inc. develops and supplies high-performance micro devices and systems to customers |

|operating in the fields of: • advanced structures, • biomedicine, • radiation imaging and detection, |

|and |

| |

|Morphonix LLC |

|Sausalito, CA |

|Karen Littman |

|Tel: 415-331-5010 |

|Email: kl@ |

| |

|For the past 17 years, Morphonix LLC has developed innovative programs in new media to better educate |

|and support children. It has released award-winning, entertaining, immersive learning games that make |

|the complex concepts of brain science fun for children and teens. From the acclaimed Journey Into The |

|Brain (for ages 7-11) to the soon-to-be released Neuromatrix (ages 11-14), Morphonix is serving a |

|critical market that everyone can relate to. The huge need for alternative, challenging tools to |

|stimulate kids in schools and at home has put the focus on Morphonix, which now serves consumers at |

|home and schools (with supplemental learning materials). Neuromatrix, bound to be a hit, includes a |

|captivating story and game set in an immersive environment, allowing kids to use their brains to learn|

|about the brain. Morphonix's video games are cool enough to play at home, smart enough to play at |

|school. Morphonix seeks developmental and/or licensing partners to take the rich content and strong |

|titles it has developed to a new level. |

| |

|Nanogen, Inc. |

|San Diego, CA |

|Dalibor Hodko |

|Tel: 858-410-4718 |

|Email: dhodko@ |

| |

|Potential threat of pandemic flu and emerging infectious diseases emphasized the need for diagnostic |

|systems capable to rapidly recognize diseases with potential epidemiologic consequences. Nanogen is |

|one of the leaders in the microarray-based DNA analysis and its electronic microarray technology |

|offers speed, accuracy and high levels of multiplexing to molecular diagnostics customers. The |

|proposed centrifugal microfluidics based system for sample preparation integrates the electronic |

|microarray detection technology into a portable instrument. A fully developed technology will yield a |

|point-of-care system with exchangeable CDs allowing choice of the pathogen detection panels including |

|respiratory infectious diseases, biological warfare agents or emergent viruses’ panels. |

| |

|Nanoprobes, Incorporated |

|Yaphank, NY |

|Richard Powell |

|Tel: 919-845-6324 |

|Email: rpowell@ |

| |

|Nanoprobes researches and develops novel technology based on the use of metal nano-particles as |

|reagents for the detection and visualization of biological targets. Current commercial products |

|include X-ray contrast agents for MicroCT and research, immunogold reagents and probes, combined |

|fluorescent and gold probes, and ultra-sensitive detection methods for in situ hybridization, |

|microscopic and blotting applications. The company develops technology and reagents for medical |

|imaging and the diagnosis of disease using nanoparticle-based contrast agents and markers, and is also|

|engaged in the development of novel therapeutics based on the enhancement of other therapeutic |

|modalities, such as radiation, by metal nano-particle-based reagents. |

| |

|Neurobiotex, Inc. |

|Galveston, TX |

|Christopher Frederickson |

|Tel: 409-762-0678 |

|Email: c.j.frederickson@ |

| |

|Neurobiotex is a science based company specializing in discovery and invention in the area of zinc in |

|biology. Combining business and scientific expertise we have patents pending on products to measure, |

|control and modulate free zinc. Our research tools, as well as our developing diagnostics and |

|therapeutics focus on early detection and preventive applications in the areas of neurological |

|diseases, cancer and diabetes. We believe this is the future of medicine and that development of our |

|technology shall enhance economic development in our country while significantly decreasing healthcare|

|expenditures. |

| |

|NeuroScript |

|Tempe, AZ |

|Hans-Leo Teulings |

|Tel: 480-350-9200 |

|Email: hlteulings@ |

| |

|NeuroScript is the only company in the world developing and marketing PC software to record and |

|automatically analyze handwriting movements. Our PC software (MovAlyzeR) requires only off-the-shelf |

|hardware. MovAlyzeR makes the seemingly complex measurement and processing of pen movements easy to |

|use after a brief learning period. Currently, MovAlyzeR is used by researchers in kinesiology, |

|experimental psychology, psychiatry, neurology, occupational therapy, aging, handwriting instruction, |

|child development, forensic handwriting analysis, computer science and by university students for |

|their graduation and course projects. Although these markets are small, they will eventually spawn |

|applications satisfying latent needs in several larger groups of health-care professionals or even the|

|general public of consumers. |

| |

|NexBio, Inc. |

|San Diego, CA |

|Mang Yu |

|Tel: 858-452-2631 |

|Email: myu@ |

| |

|In recent years the world has witnessed the escalating outbreaks of avian influenza viruses in humans.|

|The inadequacy of current prophylactic and therapeutic modalities has become all too clear. In |

|response, NexBio, Inc. is developing broad-spectrum therapeutic and prophylactic agents to protect the|

|public from all annual and pandemic variations of influenza, as well as from other life-threatening |

|respiratory viral infections. Our mission is to develop novel, broad-spectrum prophylaxis and |

|therapeutics for the prevention and treatment of serious or life-threatening human respiratory |

|infectious diseases. |

| |

|Nextek Mobility Corporation |

|Albuquerque, NM |

|Brock Roberts |

|Tel: 505-798-9818 |

|Email: Brock@ |

| |

|Nextek Mobility Corporation has developed a new all-wheel drive powered wheelchair with a zero turning|

|radius. The new technology is called PAWS or Parallel- All Wheel Steering and provides excellent |

|maneuverability and incredible off-road performance. Potential customers include power wheelchair |

|users who wish to access outdoor and rough terrain without sacrificing the maneuverability required |

|indoors. |

| |

|Nitrate Elimination Company, Inc |

|Lake Linden, MI |

|Ellen R Campbell |

|Tel: 906-296-1000 |

|Email: ellenr@ |

| |

|NECi, The Nitrate Elimination Company, Inc, is pioneering the migration of enzyme-based analytical |

|methods from research and biomedical fields into the mainstream analytical chemistry community. NECi's|

|introduction of recombinant nitrate reductase (NaR) has made enzyme-based nitrate analysis practical: |

|NaR is produced in commercial quantities with consistent performance properties at affordable cost. |

|NaR replaces the toxic cadmium reagents in use today for nitrate testing in water, public health, |

|agriculture, industry, and the environment. Applications range from test kits for field use to |

|reagents for commercial testing labs. NECi seeks partnering, distribution, and supplier agreements for|

|bulk enzyme and/or for complete test kits. |

| |

|Nonlinear Ion Dynamics, LLC |

|Panorama City, CA |

|Alfred Wong |

|Tel: 818-901-8455 |

|Email: awong@ |

| |

|NID develops a patented PEP technology to efficiently enrich a wide range of stable isotopes for |

|medical, industrial and research applications. Currently, most stable isotopes are imported from |

|foreign countries like Russia. With its advanced technology, NID can address most unmet market needs |

|of stable isotopes, including a wide variety of research isotopes and new medical and industrial |

|stable isotopes. NID provides a US based supply for stable isotopes at competitive price and higher |

|quality. NID aims to become the domestic comprehensive supplier of stable isotopes. |

| |

|O.D.260 Inc |

|Boise, ID |

|Xavier Danthinne |

|Tel: 208-345-7369 |

|Email: xdanthin@ |

| |

|O.D.260 Inc. is an emerging biotech company that develops, manufactures and markets tools for gene |

|technologies. We focus on adenovirus-based gene transfer, and we have unique scientific expertise and |

|technological capabilities in the development of bipartite and conditionally-replicating adenoviruses.|

|The company has recently developed a novel system that will add gutless (helper-dependent) adenovirus |

|construction to its proprietary product offerings. Having provided custom cloning services for more |

|than 5 years, O.D.260 has formed a solid customer base in 3 continents. We are currently looking for |

|partners to extend that service business segment and to market our research kit products |

| |

|Optimum Therapeutics, LLC |

|Columbus, OH |

|Ze Lu |

|Tel: 614-688-5885 |

|Email: zlu@ |

| |

|Optimum Therapeutics, LLC is a small, research-intensive biotech company with a focus on developing |

|products to address unmet needs in the treatment of patients with solid tumors. Currently, products to|

|enhance the effectiveness of chemo- and radio-therapy and to reduce the impact of side effects are in |

|clinical and preclinical stages of development. |

| |

|Organizational Wellness & Learning Systems |

|Fort Worth, TX |

|Joel Bennett |

|Tel: 817-845-2772 |

|Email: owls@ |

| |

|Organizational Wellness & Learning Systems, Inc has developed IntelliPrev™, a patent-pending, |

|web-based platform for HR professionals that enables them to monitor employee perceptions, assess |

|corporate wellness needs, design science-based solutions, shop for wellness vendors, and access tools |

|and training on critical tasks that directly affect their own professional success, including |

|projecting and comparing ROI, securing executive buy-in, preparing their organizations for program |

|delivery, and evaluating program success. IntelliPrev™ is currently seeking “smart” capital, key |

|strategic relationships and one or two outstanding industry professionals to lead this division. |

| |

|ORIGINUS, INC. |

|ANN ARBOR, MI |

|Maria Ines Morano |

|Tel: 734-913-8791 |

|Email: imorano@ |

| |

|Originus Inc. is a biotechnology company found in 2001 by four internationally known scientists from |

|the University of Michigan. With a focus in neuroscience, Originus supplies the Pharma/Biotech |

|industry with high quality cell-based research results and assay products. We specialize in |

|state-of-the-art solid phase transfection using STEP technology, a protein expression protocol, |

|exclusively licensed from the University of Michigan. Using our expertise in complex biological |

|systems, we develop transfection-based assays and functional screening technologies for |

|cost-effective, accelerated, rational and predictive drug discovery. Originus Inc. is seeking |

|Licensing and Partnering with pharmaceutical, biotech or supplier companies. |

| |

|Phase V Pharmaceuticals, Inc. |

|Silver Spring, MD |

|Dwayne Leslie |

|Tel: 301-495-0786 |

|Email: dleslie@ |

| |

|Phase V Pharmaceuticals, Inc. develops new formulations for drugs used to treat central nervous system|

|(CNS) injury. We focus on the special needs of 1.5 million people with a severe traumatic brain |

|injury, spinal cord injury, or cerebral palsy. Our SBIR-supported product improves the care of |

|patients with both spasticity (uncontrolled high muscle tone) and dysphagia (difficulty swallowing) by|

|providing a liquid formulation of baclofen, the first line anti-spastic medication. Phase V's |

|development pipeline addresses over $500 million of the $5 billion spent annually on drugs for this |

|patient population. |

| |

|Phoenix Biosystem, Inc. |

|Pleasanton, CA |

|Kumar Subramanian |

|Tel: 925-998-5075 |

|Email: kumar@ |

| |

|Phoenix Biosystem is developing a proprietary integrated system for automated, small volume, blood |

|sampling and analysis. The best-in-class nano volume sensor based technology provides a platform for |

|highly accurate, cost effective, one step, painless, easy-to-use testing procedures. The product |

|improves patient convenience by automating what traditionally has been a manual, multi-step process of|

|lancing, blood droplet formation, and sample collection. Phoenix Biosystem’s first product will |

|address the unmet self-testing needs of diabetics. The diabetic patient population is stubbornly |

|non-compliant for a combination of reasons including unawareness of the disease, general apathy, cost,|

|and the inconvenience and pain of testing. Phoenix Biosystem's solution of painless, One Step, |

|ease-of-use testing using a very fine lancet, very small drop of blood, and a cost effective automated|

|one step operation will help improve patient compliance substantially. Phoenix Biosystem has raised |

|funds in excess of $2.5 million and has established clinical feasibility of the technology. Phoenix |

|Biosystem is currently seeking to raise $7 Million. The Company expects to use the proceeds to |

|complete the product development and initiate FDA filing. |

| |

|Physical Sciences |

|Andover, MA |

|Mark Druy |

|Tel: 978-738-8195 |

|Email: druy@ |

| |

|Physical Sciences's Inc (PSI) goal is to bridge the gap between the federal government and prime |

|contractors in the research, development and deployment of technology for the U.S. Government. As a 33|

|year old company, PSI has an international reputation for technical excellence and innovation. We have|

|successfully developed and transitioned advanced technologies to support the missions of the |

|Department of Defense, NASA, NIH, and many commercial partners. We are dedicated to the role of |

|applying scientific and engineering innovation to solve technological problems while simultaneously |

|promoting internal product development and ultimate transition to government applications or |

|commercial offering. |

| |

|Phyto-Technologies, Inc. |

|Woodbine, IA |

|Albert Leung |

|Tel: 712-647-2755 |

|Email: ayl@ |

| |

|Phyto-Technologies’ Phyto B/P Profiling™ has successfully bridged the gap between the World’s rich |

|herbal wisdom and modern science. Now, therapeutic, cosmetic and supplement products with the |

|reproducibility, quality control and intellectual property protection commensurate with modern drugs |

|can be developed at a fraction of the latter’s cost. Furthermore, conscientious and knowledgeable |

|researchers and manufacturers who understand the importance of well-defined and appropriately |

|characterized botanical starting materials for achieving reproducible research and quality products |

|can benefit from our unique Representative Botanical Reference/Research Materials™ (RBRM™). We offer a|

|variety of unique market-ready products, developed from our grant-supported research, for licensing |

|and sale. |

|Sitemap   |   2007-08 NIH-CAP |

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download